AGTR1 and neoplasm: In vitro and in vivo experiments on OC cell lines have shown that Candesartan, an AT1 receptor antagonist, can not only inhibit the invasion ability of tumor cells in vitro, but also inhibit the growth and progression of tumor and the formation of blood vessels in mice (84, 88).